

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

APPOINTMENT OF CO-PRESIDENT

The board of directors (the “**Board**”) of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Wu Hao (吳灝) (“**Mr. Wu**”) was appointed as co-president of the Company at the seventeenth meeting of the fourth session of the Board. The term of office of Mr. Wu as co-president will take effect from August 10, 2021 until the expiry of the term of the fourth session of the Board.

The Board would like to take this opportunity to extend a warm welcome to Mr. Wu on his appointment. The biographical details of Mr. Wu are set out as follows:

Mr. Wu Hao (吳灝), aged 54, joined the Group in January 2020. Mr. Wu has over 17 years of experience in the pharmaceutical industry and has extensive marketing and business development experience. Prior to joining the Group, Mr. Wu served successively as a sales manager and a product/project manager of Schering Plough Pharmaceutical Co., Ltd.* (先靈葆雅製藥有限公司) from August 1994 to October 1999, product manager of Shanghai Roche Pharmaceutical Co., Ltd.* (上海羅氏製藥有限公司) from October 1999 to December 2002, marketing director of Eisai China Inc.* (衛材(中國)製藥有限公司) from January 2003 to July 2007, director of marketing and business development department of SciClone International Pharmaceutical Co., Ltd.* (賽生國際製藥有限公司) from August 2007 to January 2009 and the general manager of Meixin Insurance Broker (Shanghai) Co., Ltd. (美信保險經紀(上海)有限公司) from March 2010 to January 2020.

Mr. Wu obtained his bachelor's degree in clinical medicine from Shanghai Jiao Tong University School of Medicine (formerly known as Shanghai Second Medical University) in 1992 and an EMBA degree from China Europe International Business School in 2009.

Mr. Wu has entered into an employment contract with the Company for a term commencing on January 13, 2020 and ending on January 13, 2023. Mr. Wu will not enter into a separate service agreement with the Company in relation to his appointment as the co-president of the Company. The emoluments of Mr. Wu in relation to his role in the Company is determined by the Board according to the remuneration policy of the Company and with reference to his duties and responsibilities within the Group as well as his qualifications and experience. His emoluments was approximately RMB0.89 million (before tax) for the year ended December 31, 2020. Mr. Wu will not receive additional emoluments for his appointment as the co-president of the Company.

Save as disclosed above, Mr. Wu has confirmed that, as at the date of this announcement, he (i) does not hold any directorship in any public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, (ii) does not have any relationship with any of the directors, general manager, supervisors, senior management, substantial shareholders or controlling shareholders of the Company as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), or (iii) does not hold any other position in the Company or any other member of the Group.

As at the date of this announcement, Mr. Wu does not have any interest in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter relating to the appointment of Mr. Wu that needs be brought to the attention of the shareholders of the Company.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, August 10, 2021

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Ms. Yin Zhuan; the independent non-executive directors of the Company are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.

** For identification purposes only*